Publications by authors named "Shengjiang Song"
Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
J Hepatocell Carcinoma
December 2022
Article Synopsis
- The study investigates the safety and effectiveness of hepatectomy (liver surgery) after conversion therapy for patients with initially unresectable hepatocellular carcinoma (HCC) compared to direct hepatectomy.
- A total of 745 patients were analyzed, with 41 undergoing conversion therapy before surgery; those patients experienced longer operation times, increased blood loss, and a higher rate of complications.
- Despite these challenges, all patients in the conversion group had successful resection, and while some had recurrence or metastasis, there were no reported deaths, highlighting the importance of careful preoperative evaluation.
Article Synopsis
- Unresectable hepatocellular carcinoma (u-HCC) has a poor prognosis, but combination treatments like hepatic arterial infusion chemotherapy (HAIC) along with PD-1 inhibitors and tyrosine kinase inhibitors (TKIs) are becoming standard in systemic therapy.
- In a retrospective study of 145 patients with u-HCC, results showed a 57.2% overall response rate and an 89.7% disease control rate, with significant efficacy in patients without vascular invasion or extrahepatic metastases.
- The study indicated that patients with better liver function (Child-pugh A) had higher rates of disease control and surgical conversion compared to those with poorer function, suggesting that patient selection could influence treatment outcomes.
Background/aim: Recently, an increase in the number of asymptomatic rare benign liver tumors (BLTs) has been reported during health check-ups. It is difficult to determine the nature of partial rare BLTs and not easy to distinguish from malignant liver tumors. This study aimed to analysis clinical features, diagnosis and treatment of rare BLTs to reduce misdiagnosis and provide reference for clinical practice.
View Article and Find Full Text PDF